Department of Molecular Biology, University of California, San Diego, La Jolla, CA 92093, USA.
Immunity. 2011 Sep 23;35(3):413-25. doi: 10.1016/j.immuni.2011.06.013. Epub 2011 Sep 8.
Recent studies have documented genome-wide binding patterns of transcriptional regulators and their associated epigenetic marks in hematopoietic cell lineages. In order to determine how epigenetic marks are established and maintained during developmental progression, we have generated long-term cultures of hematopoietic progenitors by enforcing the expression of the E-protein antagonist Id2. Hematopoietic progenitors that express Id2 are multipotent and readily differentiate upon withdrawal of Id2 expression into committed B lineage cells, thus indicating a causative role for E2A (Tcf3) in promoting the B cell fate. Genome-wide analyses revealed that a substantial fraction of lymphoid and myeloid enhancers are premarked by the poised or active enhancer mark H3K4me1 in multipotent progenitors. Thus, in hematopoietic progenitors, multilineage priming of enhancer elements precedes commitment to the lymphoid or myeloid cell lineages.
最近的研究记录了转录调节因子及其相关表观遗传标记在造血细胞谱系中的全基因组结合模式。为了确定在发育过程中表观遗传标记是如何建立和维持的,我们通过强制表达 E 蛋白拮抗剂 Id2 生成了造血祖细胞的长期培养物。表达 Id2 的造血祖细胞是多能的,并且在 Id2 表达被撤回后很容易分化为定向 B 细胞谱系细胞,这表明 E2A(Tcf3)在促进 B 细胞命运中起着因果作用。全基因组分析显示,大量的淋巴样和骨髓样增强子在前多能祖细胞中被预先标记为有潜力或活跃的增强子标记 H3K4me1。因此,在造血祖细胞中,增强子元件的多谱系启动先于向淋巴样或骨髓样细胞谱系的定向。